Navigation Links
Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007

Radi Medical Systems Sponsors Case Review with Drs. Morton Kern, Nico

Pijls, Augusto Pichard

UPPSALA, Sweden and WILMINGTON, Mass., Oct. 19 /PRNewswire/ -- The use of fractional flow reserve (FFR) for optimizing patient outcomes is the topic of several sessions at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, which will take place Oct. 20-25 in Washington.

Radi Medical Systems AB, the first company to develop systems that calculate FFR with the physiologic assessment of targeted lesions, is sponsoring a breakfast session, Nine Cases That Will Change Your Practice: FFR Case Review, at 7 a.m. EDT on Oct. 23 in room No. 152 B in the Washington Convention Center. Morton J. Kern, M.D., of the University of California- Irvine, is the session's moderator, while Nico Pijls, M.D., Ph.D. of Catharina Hospital, Eindhoven, the Netherlands, and Augusto Pichard, M.D., of the Washington Hospital Center, are the participating faculty.

In addition to coverage in the case review, FFR and physiologic lesion assessment are the subject of:

-- An extensive workshop at 2 p.m. on Oct. 21 that will focus on the

basics of FFR measurement, the use of FFR in specific settings, and the

practicalities and impact of FFR in the era of drug-eluting stents

(Room 147AB)

-- A session on Oct. 22 during the "Board Review Course with Self

Assessment for Interventional Cardiology and Endovascular Medicine,

PART 3: Coronary Essentials" that will cover IVUS and physiologic

lesion assessment in clinical practice and physiologic lesion

assessment case presentations with an integrated Q&A (Room 146AB)

About FFR

FFR expresses maximum achievable blood flow in a coronary artery with abnormal stenosis as a fraction of normal maximum blood flow in the absence of a stenosis. It is calculated using an interventional guidewire with a specially designed sensor built into it. Using the well established value of 0.75, FFR is 100% specific in identifying which lesions are actually causing flow restriction and can be treated. FFR also documents the exact percentage of the reduction in flow associated with each lesion.

About Radi Medical Systems AB

Radi Medical Systems AB (Radi) develops, manufactures and sells medical devices designed to improve patient care. The company's pioneering work in the field of interventional cardiology has resulted in market-leading intravascular sensors and hemostasis management and radiology devices. Radi works closely with medical practitioners to develop solutions that address clinical needs, as well as provide clinical education support. Founded in 1988, Radi employs more than 350 people globally and has representation in more than 40 countries. The company is based in Uppsala, Sweden, and maintains a U.S. headquarters in Wilmington, Mass. For more information, visit

Editor's Note: Radi Medical Systems will display its latest products at booth No. 2085 at TCT 2007.

Media Contacts:

David Schull or Benjamin Carmichael

Russo Partners

+1 212-845-4271

+1 858-717-2310 (during TCT 2007)

Jim Archetto

Radi Medical Systems

+1 877-337-7234 ext. 812

SOURCE Radi Medical Systems AB
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
2. Optimizing pfuturbo DNA Polymerase Amplification Reactions with Perfect Match PCR Enhancer
3. Optimizing electroporation parameters
4. Optimizing Büchi® Rotary Evaporator Applications
5. Optimizing electroporation parameters
6. Optimizing Büchi® Rotary Evaporator Applications
7. Optimizing Bchi Rotary Evaporator Applications
8. Optimizing electroporation parameters
9. Optimizing electroporation parameters
10. Optimizing electroporation parameters
11. Optimizing electroporation parameters
Post Your Comments:
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... ...
Breaking Biology News(10 mins):